Dr. Anna Berry is a nationally recognized thought leader in molecular pathology, genomics and laboratory medicine. Since 2014, she has served as the Deputy Director for Molecular Pathology and Genomics, and as the Scientific Director for the Personalized Medicine Program at the Swedish Cancer Institute in Seattle. Since 2014, she has also served as Director of Genomics Programs at CellNetix Pathology and Laboratories.

Dr. Berry has board certifications in anatomic pathology and clinical pathology, cytopathology, and molecular genetic pathology. She has participated in a range of impactful roles relating to her expertise, to include committees and working groups, nationally and internationally. Dr. Berry will work in partnership with Syapse’s functional leaders to support product and service development, serve as a subject matter expert to Syapse’s customers, participate in joint-authored research and publications, and advance Syapse’s thought leadership efforts in the area of real-world evidence.